Positions

Overview

  • My research is focused on the use of monoclonal antibodies that bind cancer cell surface receptors for cancer therapy in combination with chemotherapy agents, Wnt inhibitors, or radiation. This research involves investigation of the mechanisms of enhanced cytotoxicity produced by combination treatment. Orthotopic and metastatic breast, ovarian, and pancreatic cancer xenograft models are being used to optimize therapeutic regimens in collaboration with investigators from the Divisions of Gynecologic Oncology and Hematology/Oncology at UAB. We are also investigating the use of small molecule inhibitors of the Wnt pathway produced at Southern Research for cancer therapy and targeting of cancer initiating cells in breast, ovarian, and pancreatic cancer models. Other research involves cancer treatment with alpha-particle emitters conjugated to monoclonal antibodies. In collaboration with investigators at HudsonAlpha Institute for Biotechnology, we are investigating the use of genomics to predict the response of patients with triple-negative breast cancer, ovarian cancer, or pancreatic cancer treated with chemotherapy. Recent efforts involve the use of histone deacetylase inhibitors to upregulate the MHCII pathway and immune response against syngeneic breast and ovarian cancer models, which is being investigated in combination with checkpoint inhibitor therapy.

    • Selected Publications

    Academic Article

    Year Title Altmetric
    2019 The expression of MHC class II molecules on murine breast tumors delays T-cell exhaustion, expands the T-cell repertoire, and slows tumor growth 2019
    2018 The antitumor effects of entinostat in ovarian cancer require adaptive immunity 2018
    2018 Calmodulin antagonist enhances DR5-mediated apoptotic signaling in TRA-8 resistant triple negative breast cancer cells 2018
    2018 Corrigendum to ‘212Pb-labeled B7-H3-targeting antibody for pancreatic cancer therapy in mouse models’ [Nucl Med Biol 58 (2018) 67–73] (S0969805117303396) (10.1016/j.nucmedbio.2017.12.004)) 2018
    2018 Retraction notice to “SRI36160 is a specific inhibitor of Wnt/<beta>-catenin signaling in human pancreatic and colorectal cancer cells” [Canc. Lett. 389C (2017) 41–48] (S030438351630800X) (10.1016/j.canlet.2016.12.030)) 2018
    2018 Preferential inhibition of Wnt/β-catenin signaling by novel benzimidazole compounds in triple-negative breast cancer 2018
    2018 Correction: Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer [Oncotarget., 7, (2016) (86803-86815)] 10.18632/oncotarget.13466 2018
    2018 212Pb-labeled antibody 225.28 targeted to chondroitin sulfate proteoglycan 4 for triple-negative breast cancer therapy in mouse models 2018
    2018 212Pb-labeled B7-H3-targeting antibody for pancreatic cancer therapy in mouse models 2018
    2018 CD38 pretargeted RIT of B-cell tumors 2018
    2018 ST6Gal-I sialyltransferase promotes chemoresistance in pancreatic ductal adenocarcinoma by abrogating gemcitabine-mediated DNA damage 2018
    2017 Modulation of antitumor immunity with histone deacetylase inhibitors 2017
    2017 Survivin a radiogenetic promoter for glioblastoma viral gene therapy independently from CArG motifs. 2017
    2017 Calmodulin Binding to Death Receptor 5-mediated Death-Inducing Signaling Complex in Breast Cancer Cells 2017
    2017 Epigenetic therapy for the treatment of epithelial ovarian cancer: A clinical review 2017
    2017 B7-H3-targeted 212Pb radioimmunotherapy of ovarian cancer in preclinical models 2017
    2017 SRI36160 is a specific inhibitor of Wnt/β-catenin signaling in human pancreatic and colorectal cancer cells 2017
    2017 Retraction of "Design and Synthesis of Novel Cyclic Amine Benzimidazoles for the Treatment of Pancreatic Cancer". 2017
    2017 Epigenetic modifiers upregulate MHC II and impede ovarian cancer tumor growth 2017
    2017 Genomic regulation of invasion by STAT3 in triple negative breast cancer 2017
    2017 Journey of TRAIL from bench to bedside and its potential role in immuno-oncology 2017
    2016 RNA sequencing of pancreatic adenocarcinoma tumors yields novel expression patterns associated with long-term survival and reveals a role for ANGPTL4 2016
    2016 Ovarian cancer and the immune system — The role of targeted therapies 2016
    2016 Role of nanotechnology and gene delivery systems in TRAIL-based therapies 2016
    2016 The tumor-associated glycosyltransferase ST6Gal-I regulates stem cell transcription factors and confers a cancer stem cell phenotype 2016
    2016 Characterization of the interactions between calmodulin and death receptor 5 in triple-negative and estrogen receptor-positive breast cancer cells: An integrated experimental and computational study 2016
    2016 A Novel Imaging Biomarker Extracted from Fluorescence Microscopic Imaging of TRA-8/DR5 Oligomers Predicts TRA-8 Therapeutic Efficacy in Breast and Pancreatic Cancer Mouse Models 2016
    2016 Expression of the MHC Class II Pathway in Triple-Negative Breast Cancer Tumor Cells Is Associated with a Good Prognosis and Infiltrating Lymphocytes. 2016
    2016 SPARC-independent delivery of nab-paclitaxel without depleting tumor stroma in patient-derived pancreatic Cancer xenografts 2016
    2016 Surveying the serologic proteome in a tissue-specific kras(G12D) knockin mouse model of pancreatic cancer 2016
    2016 Targeting the Wnt/β-catenin pathway in primary ovarian cancer with the porcupine inhibitor WNT974 2016
    2016 Loss of tumor suppressor Merlin results in aberrant activation of Wnt/β-catenin signaling in cancer 2016
    2016 Niclosamide and its analogs are potent inhibitors of Wnt/ß- catenin, mTOR and STAT3 signaling in ovarian cancer 2016
    2015 Targeted radiotherapy potentiates the cytotoxicity of a novel anti-human DR5 monoclonal antibody and the adenovirus encoding soluble TRAIL in prostate cancer 2015
    2015 Dynamic contrast enhanced magnetic resonance imaging of an orthotopic pancreatic cancer mouse model 2015
    2015 S100A4 promotes pancreatic cancer progression through a dual signaling pathway mediated by Src and focal adhesion kinase 2015
    2015 Dynamic contrast enhanced magnetic resonance imaging of an orthotopic pancreatic cancer mouse model 2015
    2015 Niclosamide analogs for treatment of ovarian cancer 2015
    2015 Ovarian and cervical cancer patient derived xenografts: The past, present, and future 2015
    2014 Ovarian cancer stem cells: Can targeted therapy lead to improved progression-free survival? 2014
    2014 Pazopanib combined with radiation: In vivo model of interaction 2014
    2014 Multi-targeted therapy of cancer by niclosamide: A new application for an old drug 2014
    2014 Loss of N-Myc interactor promotes epithelial-mesenchymal transition by activation of TGF-β/SMAD signaling 2014
    2014 Antagonistic effects of anti-EMMPRIN antibody when combined with chemotherapy against hypovascular pancreatic cancers 2014
    2014 Will detection of microRNA biomarkers in blood improve the diagnosis and survival of patients with pancreatic cancer? 2014
    2014 Combination therapy with anti-DR5 antibody and tamoxifen for triple negative breast cancer 2014
    2014 Effect of niclosamide on basal-like breast cancers 2014
    2014 Experimental virotherapy of chemoresistant pancreatic carcinoma using infectivity-enhanced fiber-mosaic oncolytic adenovirus 2014
    2014 Inhibition of Wnt/β-catenin pathway by niclosamide: A therapeutic target for ovarian cancer 2014
    2014 MicroRNA results may differ with age 2014
    2014 Monoclonal antibody-based immunotherapy of ovarian cancer: Targeting ovarian cancer cells with the B7-H3-specific mAb 376.96 2014
    2014 Recurrent read-through fusion transcripts in breast cancer 2014
    2013 The Wnt/β-catenin pathway in ovarian cancer: A review 2013
    2013 Catalase abrogates β-lapachone-induced PARP1 hyperactivation-directed programmed necrosis in NQO1-positive breast cancers 2013
    2013 Lung resistance-related protein (LRP) expression in malignant ascitic cells as a prognostic marker for advanced ovarian serous carcinoma 2013
    2013 ST6Gal-I protein expression is upregulated in human epithelial tumors and correlates with stem cell markers in normal tissues and colon cancer cell lines 2013
    2013 The C-Terminal Region Mesd Peptide Mimics Full-Length Mesd and Acts as an Inhibitor of Wnt/β-Catenin Signaling in Cancer Cells 2013
    2013 KM method in estimation of Tumor Doubling time in Animal experiment 2013
    2012 A review of B7-H3 and B7-H4 immune molecules and their role in ovarian cancer 2012
    2012 A deimmunized bispecific ligand-directed toxin that shows an impressive anti-pancreatic cancer effect in a systemic nude mouse orthotopic model 2012
    2012 Basal-like breast cancer stem cells are sensitive to anti-DR5 mediated cytotoxicity 2012
    2012 Effect of anti-DR5 and chemotherapy on basal-like breast cancer 2012
    2012 The impact of novel retinoids in combination with platinum chemotherapy on ovarian cancer stem cells 2012
    2012 Progress in cancer therapy 2012
    2012 The use of retinoids in ovarian cancer: A review of the literature 2012
    2012 Cancer Treatment with Gene Therapy and Radiation Therapy 2012
    2011 Treatment of small cell lung cancer with TRA-8 in combination with cisplatin and radiation 2011
    2011 Cellular model of Warburg Effect identifies tumor promoting function of UCP2 in breast cancer and its suppression by genipin 2011
    2011 Relationship between galectin-3 expression and TRAIL sensitivity in breast cancer 2011
    2011 Molecular targeted approaches for treatment of pancreatic cancer 2011
    2011 Thrombospondin-1 opens the paracellular pathway in pulmonary microvascular endothelia through EGFR/ErbB2 activation 2011
    2011 Early therapy evaluation of combined cetuximab and irinotecan in orthotopic pancreatic tumor xenografts by dynamic contrast-enhanced magnetic resonance imaging 2011
    2011 A phase i study evaluating the role of the anti-epidermal growth factor receptor (EGFR) antibody cetuximab as a radiosensitizer with chemoradiation for locally advanced pancreatic cancer 2011
    2011 Anti-tumor activity of an anti-DR5 monoclonal antibody, TRA-8, in combination with taxane/platinum-based chemotherapy in an ovarian cancer model 2011
    2011 Mechanisms of drug sensitization to TRA-8, an agonistic death receptor 5 antibody, involve modulation of the intrinsic apoptotic pathway in human breast cancer cells 2011
    2011 Combined modality therapy with TRAIL or agonistic death receptor antibodies 2011
    2011 DCE-MRI detects early vascular response in breast tumor xenografts following anti-DR5 Therapy 2011
    2011 Evaluation of the Effectiveness of Two Drugs Combination Therapy in Vitro Cytotoxicity Study 2011
    2010 KISS1 over-expression suppresses metastasis of pancreatic adenocarcinoma in a xenograft mouse model 2010
    2010 Overcoming TRAIL resistance in ovarian carcinoma 2010
    2010 A new drug delivery method of bispecific ligand-directed toxins, which reduces toxicity and promotes efficacy in a model of orthotopic pancreatic cancer 2010
    2009 Monoclonal antibodies in the treatment of pancreatic cancer 2009
    2009 Experimental cancer therapy using restoration of NAD+-linked 15-hydroxyprostaglandin dehydrogenase expression 2009
    2009 CRAdRGDflt-IL24 virotherapy in combination with chemotherapy of experimental glioma 2009
    2009 Effect of TRA-8 anti-death receptor 5 antibody in combination with chemotherapy in an ex vivo human ovarian cancer model 2009
    2009 Polyethylene glycosylated curcumin conjugate inhibits pancreatic cancer cell growth through inactivation of Jab1 2009
    2009 Altered expression of 15-hydroxyprostaglandin dehydrogenase in tumor-infiltrated CD11b myeloid cells: A mechanism for immune evasion in cancer 2009
    2009 Anti-EMMPRIN monoclonal antibody as a novel agent for therapy of head and neck cancer 2009
    2009 Preclinical studies and clinical utilization of monoclonal antibodies in epithelial ovarian cancer 2009
    2009 Therapy of head and neck squamous cell carcinoma with replicative adenovirus expressing tissue inhibitor of metalloproteinase-2 and chemoradiation 2009
    2008 In vivo efficacy of marimastat and chemoradiation in head and neck cancer xenografts 2008
    2008 In Reply to Dr. Speer 2008
    2008 Immunohistochemistry in the evaluation of neovascularization in tumor xenografts 2008
    2008 Molecular chemotherapy of pancreatic cancer using novel mutant bacterial cytosine deaminase gene 2008
    2008 Early therapy evaluation of combined anti-death receptor 5 antibody and gemcitabine in orthotopic pancreatic tumor xenograftsby diffusion-weighted magnetic resonance imaging 2008
    2008 Molecular targeted therapies for pancreatic cancer 2008
    2008 Combination of treatment with death receptor 5-specific antibody with therapeutic HPV DNA vaccination generates enhanced therapeutic anti-tumor effects 2008
    2008 Enhancement of Glioma Radiotherapy and Chemotherapy Response With Targeted Antibody Therapy Against Death Receptor 5 2008
    2008 Effect of TRA-8 anti-DR5 monoclonal antibody in combination with chemotherapy in an ex vivo human ovarian cancer model. 2008
    2008 Genetically designing a more potent antipancreatic cancer agent by simultaneously co-targeting human IL13 and EGF receptors in a mouse xenograft model 2008
    2008 Treatment of human colon cancer xenografts with TRA-8 anti-death receptor 5 antibody alone or in combination with CPT-11 2008
    2008 Erratum: Mutation of Escherichia coli cytosine deaminase significantly enhances molecular chemotherapy of human glioma (Gene Therapy (2008) vol. 14 (1111-1119) 10.1038/sj.gt.3302965) 2008
    2008 Anti-tumor activity of the TRA-8 anti-DR5 antibody in combination with cisplatin in an ex vivo human cervical cancer model 2008
    2007 TRA-8 anti-DR5 monoclonal antibody and gemcitabine induce apoptosis and inhibit radiologically validated orthotopic pancreatic tumor growth 2007
    2007 EGFR Genomic Gain and Aberrant Pathway Signaling in Pancreatic Cancer Patients 2007
    2007 Brief overview of preclinical and clinical studies in the development of intraperitoneal radioimmunotherapy for ovarian cancer 2007
    2007 Combination treatment with TRA-8 anti-death receptor 5 antibody and CPT-11 induces tumor regression in an orthotopic model of pancreatic cancer 2007
    2007 Single-photon emission computed tomography imaging with a humanized, apoptosis-inducing antibody targeting human death receptor 5 in pancreas and breast tumor xenografts 2007
    2007 Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and its therapeutic potential in breast and gynecologic cancers 2007
    2007 TRAIL-receptor antibodies as a potential cancer treatment 2007
    2007 Pancreatic cancer epidermal growth factor receptor (EGFR) intron 1 polymorphism influences postoperative patient survival and in vitro erlotinib response 2007
    2007 Efficacy of anti-death receptor 5 (DR5) antibody (TRA-8) against primary human ovarian carcinoma using a novel ex vivo tissue slice model 2007
    2007 Epidermal growth factor receptor (EGFR) is highly conserved in pancreatic cancer 2007
    2007 High-resolution single-photon emission computed tomography and X-ray computed tomography imaging of Tc-99m-labeled anti-DR5 antibody in breast tumor xenografts 2007
    2007 ErbB3 expression and dimerization with EGFR influence pancreatic cancer cell sensitivity to erlotinib 2007
    2007 Mutation of Escherichia coli cytosine deaminase significantly enhances molecular chemotherapy of human glioma 2007
    2006 Oncolytic HSV-1 for the treatment of brain tumours 2006
    2006 Treatment With Gemcitabine and TRA-8 Anti-Death Receptor-5 mAb Reduces Pancreatic Adenocarcinoma Cell Viability In Vitro and Growth In Vivo 2006
    2006 Pretargeted radioimmunotherapy 2006
    2006 Inducible resistance of tumor cells to tumor necrosis factor-related apoptosis-inducing ligand receptor 2-mediated apoptosis by generation of a blockade at the death domain function 2006
    2006 TRAIL receptor-targeted therapy 2006
    2006 Anti-tumor activity of TRA-8 anti-death receptor 5 (DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer model 2006
    2006 Combination of cytosine deaminase suicide gene expression with DR5 antibody treatment increases cancer cell cytotoxicity 2006
    2006 Gene delivery and gene therapy of prostate cancer 2006
    2006 Multiple gene expression analyses in paraffin-embedded tissues by TaqMan low-density array. Application to Hedgehog and Wnt pathway analysis in ovarian endometrioid adenocarcinoma 2006
    2005 Antitumor efficacy of capecitabine and celecoxib in irradiated and lead-shielded, contralateral human BxPC-3 pancreatic cancer xenografts: Clinical implications of abscopal effects 2005
    2005 Erratum: Intraperitoneal radioimmunotherapy with a humanized anti-TAG-72 (CC49) antibody with a deleted CH2 region (Cancer Biotherapy and Radiopharmaceuticals (2005) 20, 5 (502-513)) 2005
    2005 Intraperitoneal radioimmunotherapy with a humanized anti-TAG-72 (CC49) antibody with a deleted CH2 region 2005
    2005 Intraperitoneal pretarget radioimmunotherapy with CC49 fusion protein 2005
    2005 TRAIL death receptor therapy for malignant glioma. 2005
    2005 TRAIL-mediated induction of apoptosis as a targeted therapy for prostate cancer. 2005
    2005 The small heat shock protein αB-crystallin is a novel inhibitor of TRAIL-induced apoptosis that suppresses the activation of caspase-3 2005
    2005 Combined ionizing radiation and sKDR gene delivery for treatment of prostate carcinomas 2005
    2005 Development and analyses of CPT-11 resistant sublines of human colorectal adenocarcinoma cell line, SW-948 2005
    2005 Radiotargeted gene therapy 2005
    2004 Adenovirus-mediated FLT1-targeted proapoptotic gene therapy of human prostate cancer 2004
    2004 Mechanisms of resistance to Erbitux (anti-epidermal growth factor receptor) combination therapy in pancreatic adenocarcinoma cells 2004
    2004 Site-specifically traced drug release and biodistribution of a paclitaxel-antibody conjugate toward improvement of the linker structure 2004
    2004 Detection of disseminated breast cancer growth and treatment response using non-invasive bioluminescence imaging. 2004
    2004 Enhanced apoptosis following treatment with TRA-8 anti-human DR5 monoclonal antibody and overexpression of exogenous Bax in human glioma cells 2004
    2004 Adenoviral vector-mediated augmentation of epidermal growth factor receptor (EGFr) enhances the radiosensitization properties of anti-EGFr treatment in prostate cancer cells 2004
    2004 Anti-EGFR-mediated radiosensitization as a result of augmented EGFR expression 2004
    2004 Gene expression imaging with radiolabeled peptides 2004
    2004 Imaging and Therapy of Tumors Induced to Express Somatostatin Receptor by Gene Transfer Using Radiolabeled Peptides and Single Chain Antibody Constructs 2004
    2003 Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model 2003
    2003 Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model. 2003
    2003 Differential responses by pancreatic carcinoma cell lines to prolonged exposure to Erbitux (IMC-C225) anti-EGFR antibody 2003
    2003 Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway 2003
    2003 An adenovirus encoding proapoptotic Bax synergistically radiosensitizes malignant glioma 2003
    2003 Invited commentary: targeting of 125I-labeled B lymphocyte stimulator. 2003
    2003 Synthesis and biological evaluation of paclitaxel-C225 conjugate as a model for targeted drug delivery 2003
    2003 Targeting of 125I-labeled B lymphocyte stimulator 2003
    2003 Three-dimensional dose model for the comparison of 177Lu-HuCC49ΔCH2 and 177Lu-HuCC49 radioimmunotherapy in mice bearing intraperitoneal xenografts 2003
    2002 Treatment of pancreatic cancer xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation 2002
    2002 Induction of thymidine phosphorylase in both irradiated and shielded, contralateral human U87MG glioma xenografts: Implications for a dual modality treatment using capecitabine and irradiation 2002
    2002 Adenovirus-mediated transfer of BAX driven by the vascular endothelial growth factor promoter induces apoptosis in lung cancer cells 2002
    2002 De novo synthesis of a new diethylenetriaminepentaacetic acid (DTPA) bifunctional chelating agent 2002
    2002 Synthesis of the first diethylenetriaminepentahydroxamic acid (DTPH) bifunctional chelating agent 2002
    2002 Effective single chain antibody (scFv) concentrations in vivo via adenoviral vector mediated expression of secretory scFv 2002
    2002 Model prediction of treatment planning for dose-fractionated radioimmunotherapy. 2002
    2002 Quantitation of cytosine deaminase mRNA by real-time reverse transcription polymerase chain reaction: A sensitive method for assessing 5-fluorocytosine toxicity in Vitro 2002
    2002 Rationales, evidence, and design considerations for fractionated radioimmunotherapy. 2002
    2002 Targeted radiotherapy with [(90)Y]-SMT 487 in mice bearing human nonsmall cell lung tumor xenografts induced to express human somatostatin receptor subtype 2 with an adenoviral vector. 2002
    2002 Intratumoral 5-fluorouracil produced by cytosine deaminase/5-fluorocytosine gene therapy is effective for experimental human glioblastomas 2002
    2002 Effective single chain antibody (scFv) concentrations in vivo via adenoviral vector mediated expression of secretory scFv 2002
    2002 Gamma camera dual imaging with a somatostatin receptor and thymidine kinase after gene transfer with a bicistronic adenovirus in mice 2002
    2001 Gene therapy for the treatment of cancer. 2001
    2001 Detection and measurement of in vitro gene transfer by gamma camera imaging 2001
    2001 A noninvasive reporter system to image adenoviral-mediated gene transfer to ovarian cancer xenografts 2001
    2001 An adenovirus with enhanced infectivity mediates molecular chemotherapy of ovarian cancer cells and allows imaging of gene expression 2001
    2001 Simultaneous evaluation of dual gene transfer to adherent cells by gamma-ray imaging 2001
    2001 Update: Gene therapy for the treatment of cancer 2001
    2000 Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers. 2000
    2000 A robust summarize-regress procedure for tissue-specific pharmacokinetics 2000
    2000 Molecular modification of a recombinant anti-CD3ε-directed immunotoxin by inducing terminal cysteine bridging enhances anti-GVHD efficacy and reduces organ toxicity in a lethal murine model 2000
    2000 Noninvasive monitoring of gene transfer using a reporter receptor imaged with a high-affinity peptide radiolabeled with 99mTc or 188Re 2000
    2000 A targetable, injectable adenoviral vector for selective gene delivery to pulmonary endothelium in vivo 2000
    2000 An adenovirus encoding proapoptotic Bax induces apoptosis and enhances the radiation effect in human ovarian cancer 2000
    2000 Experimental radioimmunotherapy 2000
    2000 Fractionated radiation therapy in combination with adenoviral delivery of the cytosine deaminase gene and 5-fluorocytosine enhances cytotoxic and antitumor effects in human colorectal and cholangiocarcinoma models 2000
    2000 Gene transfer strategies for improving radiolabeled peptide imaging and therapy 2000
    2000 Radiation to control gene expression 2000
    2000 Selectivity of tag-72-targeted adenovirus gene transfer to primary ovarian carcinoma cells versus autologous mesothelial cells in vitro 2000
    1999 Paclitaxel derivatives for targeted therapy of cancer: Toward the development of smart taxanes 1999
    1999 Mouse models for internal radiation dosimetry [4] (multiple letters) 1999
    1999 Improved synthesis of the bifunctional chelating agent 1,4,7,10- tetraaza-N-(1-carboxy-3-(4-nitrophenyl)propyl)-N',N'',N'''-tris(acetic acid)cyclododecane (PA-DOTA) 1999
    1999 Biodistribution study of 188Re-labeled trisuccin-HuCC49 and trisuccin-HuCC49deltaCh2 conjugates in athymic nude mice bearing intraperitoneal colon cancer xenografts. 1999
    1999 Comparison of multiple bolus and continuous injections of 131I-labeled CC49 for therapy in a colon cancer xenograft model. 1999
    1999 Targeting strategies for cancer radiotherapy. 1999
    1999 Monoclonal antibodies as potentiators of radiotherapy and chemotherapy in the management of head and neck cancer 1999
    1999 In vivo localization of [111In]-DTPA-D-Phe1-octreotide to human ovarian tumor xenografts induced to express the somatostatin receptor subtype 2 using an adenoviral vector 1999
    1999 Biodistribution Study of 188Re-Labeled Trisuccin-HuCC49 and Trisuccin-HuCC49ΔCH2 Conjugates in Athymic Nude Mice Bearing Intraperitoneal Colon Cancer Xenografts 1999
    1999 Combined modality therapy of A431 human epidermoid cancer using anti- EGFR antibody C225 and radiation 1999
    1999 Cytosine deaminase and herpes simplex virus thymidine kinase gene expression via adenoviral infection of human cholangiocarcinoma cells occurs in the presence of human bile 1999
    1999 Further studies on the protein conjugation of hydroxamic acid bifunctional chelating agents: Group-specific conjugation at two different loci 1999
    1999 Specific membrane receptor gene expression targeted with radiolabeled peptide employing the erbB-2 and DF3 promoter elements in adenoviral vectors 1999
    1998 Differential susceptibility of primary and established human glioma cells to adenovirus infection: Targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer 1998
    1998 Comparison of biodistribution of 131I CC49 mAb in athymic nude mice bearing LS174T colon cancer xenografts following bolus injection or continuous infusion 1998
    1998 Genetic induction of antigens and receptors as targets for cancer radiotherapy 1998
    1998 Radiosensitization mediated by a transfected anti-ERBB-2 single-chain antibody in vitro and in vivo 1998
    1998 A mouse bone marrow dosimetry model 1998
    1998 Enhanced in vivo gene delivery to human ovarian cancer xenografts utilizing a tropism-modified adenovirus vector 1998
    1998 Combined Cytosine Deaminase Expression, 5-Fluorocytosine Exposure, and Radiotherapy Increases Cytotoxicity to Cholangiocarcinoma Cells 1998
    1997 Experimental tumor targeting with radiolabeled ligands. 1997
    1997 Synthesis of bombesin analogues for radiolabeling with rhenium-188. 1997
    1997 Tumor localization of a radiolabeled bombesin analogue in mice bearing human ovarian tumors induced to express the gastrin-releasing peptide receptor by an adenoviral vector. 1997
    1997 Localization of idine-125-mIP-Des-Met14bmbesin (7-13)NH2 in ovarian carcinoma induced to express the gastrin releasing peptide receptor by adenoviral vector-mediated gene transfer 1997
    1997 Molecular chemotherapy combined with radiation therapy enhances killing of cholangiocarcinoma cells in vitro and in vivo 1997
    1997 Conjugation of unprotected trisuccin, N-[tris[2-[(N-hydroxyamino)carbonyl]ethyl]methyl]succinamic acid, to monoclonal antibody CC49 by an improved active ester protocol 1997
    1997 Adenoviral-mediated delivery of gastrin-releasing peptide receptor results in specific tumor localization of a bombesin analogue in vivo 1997
    1997 Synthesis and biodistribution of peptide based 99mTc/186Re- MAGIPG-D612 monoclonal antibody in nude mice bearing colon cancer xenografts 1997
    1997 Synthesis, rhenium-188 labeling and biodistribution studies of a phenolic ester derivative of trisuccin 1997
    1997 Use of a novel cross-linking method to modify adenovirus tropism 1997
    1996 Approaches to enhance cancer radiotherapy employing gene transfer methods 1996
    1996 Synthesis of a new class of isothiocyanatopeptide bifunctional chelating agents for coupling to monoclonal antibodies 1996
    1996 Enhancement of radiolabeled antibody binding and tumor localization through adenoviral transduction of the human carcinoembryonic antigen gene 1996
    1996 A quantitative study of radionuclide characteristics for radioimmunotherapy from 3D reconstructions using serial autoradiography 1996
    1996 Experimental radioimmunotherapy: biological effectiveness and comparison with external beam radiation. 1996
    1995 Experimental approaches to increase radiolabeled antibody localization in tumors 1995
    1995 Experimental approaches to increase radiolabeled antibody localization in tumors. 1995
    1995 Fractionated radioimmumotherapy of human colon carcinoma xenografts with131I-labeled monoclonal antibody CC49 1995
    1995 Reconciliation of tumor dose response to external beam radiotherapy versus radioimmunotherapy with 131iodine-labeled antibody for a colon cancer model 1995
    1994 A peptide-based bifunctional chelating agent for 99mTc- and 186Re-labeling of monoclonal antibodies. 1994
    1994 Radioiodination of monoclonal antibodies D612 and 17-1A with 3-iodophenylisothiocyanate and their biodistribution in tumor-bearing nude mice. 1994
    1994 Sensitization of radiolabeled monoclonal antibody therapy using bromodeoxyuridine. 1994
    1994 A peptide‐based bifunctional chelating agent for 99mtc‐ and 186re‐labeling of monoclonal antibodies 1994
    1994 Radioiodination of monoclonal antibodies d612 and 17‐1a with 3‐lodophenylisothiocyanate and their biodistribution in tumor‐bearing nude mice 1994
    1994 Sensitization of radiolabeled monoclonal antibody therapy using bromodeoxyuridine 1994
    1994 Three‐dimensional reconstruction of monoclonal antibody uptake in tumor and calculation of beta dose‐rate nonuniformity 1994
    1993 Synthesis of N-[Tris[2-[[N-(benzyloxy)amino]carbonyl]ethyl]methyl]succinamic Acid, Trisuccin. Hydroxamic Acid Derivatives as a New Class of Bifunctional Chelating Agents 1993
    1993 Comparison of 131I- and 90Y-labeled monoclonal antibody 17-1A for treatment of human colon cancer xenografts 1993
    1993 Erratum:'Variations in 3-D dose distributions for 131Indium-labeled monoclonal antibody' (Antibody,Immunoconjugates, and Radiopharmaceuticals,(1992)5(4)) 1993
    1993 Introduction: Radiolabeled antibody tumor dosimetry 1993
    1993 New azomycin acyclonucleoside. Synthesis and biodistribution of radiohalogenated analogues in tumor‐bearing mice 1993
    1992 Development of 3-iodophenylisothiocyanate for radioiodination of monoclonal antibodies 1992
    1992 Improved Delivery of Radiolabeled Anti-Bl Monoclonal Antibody to Raji Lymphoma Xenografts by Predosing with Unlabeled Anti-Bl Monoclonal Antibody 1992
    1992 Therapy with Unlabeled and 131I-labeled Pan-B-Cell Monoclonal Antibodies in Nude Mice Bearing Raji Burkitt's Lymphoma Xenografts 1992
    1992 Three-dimensional tumor dosimetry for radioimmunotherapy using serial autoradiography 1992
    1991 [125I]-IPM. Radioimmunoconjugator antibody radiolabeling reagent 1991
    1991 Radiotherapy in Mice with Yttrium-90-labeled Anti-Ly1 Monoclonal Antibody: Therapy of Established Graft-versus-Host Disease Induced across the Major Histocompatibility Barrier 1991
    1991 Radiotherapy in Mice with Yttrium-90-labeled Anti-Ly1 Monoclonal Antibody: Therapy of the T Cell Lymphoma EL4 1991
    1991 18F‐2‐deoxy‐2‐fluoro‐D‐glucose uptake into human tumor xenografts. Feasibility studies for cancer imaging with positron‐emission tomography 1991
    1991 A Sensitivity Study of Micro-TLDs for in Vivo Dosimetry of Radioimmunotherapy 1991
    1991 Effect of backscatter on cell survival for a clinical electron beam 1991
    1991 The expression of epidermal growth factor receptor on human bladder cancer: Potential use in radioimmunoscintigraphy 1991
    1990 A new conjugating agent for radioiodination of proteins: Low in vivo deiodination of a radiolabeled antibody in a tumor model 1990
    1990 A comparison of 131I-labeled monoclonal antibody 17-1A treatment to external beam irradiation on the growth of LS174T human colon carcinoma xenografts 1990
    1990 Comparison of antigen expression on normal urothelial cells in tissue section and tissue culture 1990
    1990 New trends in the use of radioimmunoconjugates for the therapy of cancer. 1990
    1989 Radioiodinated iodophenyl maleimide: A potential radioimmunoconjugate with low in vivo deiodination 1989
    1989 The role of ricin B chain in the intracellular trafficking of anti-CD5 immunotoxins 1989
    1988 Cytotoxic effects of anti-cd5 radioimmunotoxins on human tumors in vitro and in a nude mouse model 1988
    1988 Localization and Imaging of Radiolabeled Monoclonal Antibodies Against Colorectal Carcinoma in Tumor-Bearing Nude Mice 1988
    1988 Localization and Imaging with Radioiodine-labeled Monoclonal Antibodies in a Xenogeneic Tumor Model for Human B-Cell Lymphoma 1988
    1988 Localization and imaging of radiolabeled monoclonal antibodies against colorectal carcinoma in tumor-bearing nude mice 1988
    1987 Human leukemia cell binding and killing by anti-CD5 radioimmunotoxins 1987
    1986 Antigenic modulation by anti-CD5 immunotoxins 1986
    1985 Comparison of the distribution and binding of monoclonal antibodies labeled with 131-iodine or 111-indium 1985
    1985 Radiolabeling of monoclonal antibody against carcinoembryonic antigen with 88 Y and biodistribution studies 1985
    1985 Radiolabeling of monoclonal antibody against carcinoembryonic antigen with 88Y and biodistribution studies 1985
    1982 Localization of Radiolabeled Antibody in SVT2 Tumor Increases with Immunosuppression of the Host 1982
    1980 Localization of radiolabeled mouse alloantibody in a sarcoma induced by 3-methylcholanthrene 1980
    1979 Distribution of radiolabled alloantibodies in mice bearing 3-methylcholanthrene-induced sarcomas 1979
    1974 Preferential in vivo localization of 125I-labeled antibody in a carcinogen-induced syngeneic rat tumor. 1974
    1972 Effect of Rat Tumor Allografts on the Blood Level of Passively Transferred Alloantibodies 1972
    1972 Localization of an 125I-Labeled Rat Transplantation Antibody in Tumors Carrying the Corresponding Antigen 1972

    Chapter

    Year Title Altmetric
    2018 Novel Biomimetic Microphysiological Systems for Tissue Regeneration and Disease Modeling.  87-113. 2018
    2012 Drugs in clinical trials & future directions.  85-95. 2012
    2010 Cytosine Deaminase/5-Fluorocytosine Molecular Cancer Chemotherapy.  219-242. 2010
    2009 Cancer gene therapy.  589-612. 2009
    2000 Radionuclide dosimetry and radioimmunotherapy of cancer.  21-55. 2000

    Research Overview

  • Cancer immunotherapy; Targeting cancer stem cells; Precision oncology

    • Principal Investigator On

  • Comprehensive Cancer Center Core Support Grant - Inflammation, Immunology and Immunotherapeutics Program  awarded by National Cancer Institute/NIH/DHHS 2019 - 2021
  • Comprehensive Cancer Center Core Support Grant - Inflammation, Immunology and Immunotherapeutics Program  awarded by National Cancer Institute/NIH/DHHS 2017 - 2019
  • Genomic Profiling for ER+ Breast Cancer to Identify Signatures of Therapy Response  awarded by HUDSONALPHA INSTITUTE FOR BIOTECHNOLOGY 2013 - 2017
  • UAB / UMN SPORE in Pancreatic Cancer  awarded by National Cancer Institute/NIH/DHHS 2010 - 2017
  • UAB / UMN SPORE in Pancreatic Cancer - Project 2  awarded by National Cancer Institute/NIH/DHHS 2010 - 2017
  • Comprehensive Cancer Center Core Support Grant - Inflammation, Immunology and Immunotherapeutics Program  awarded by National Cancer Institute/NIH/DHHS 2016 - 2017
  • Therapy of Pancreatic Cancer With 212Pb-Labeled B7-H3 Specific Ab and LDE225  awarded by National Cancer Institute/NIH/DHHS 2014 - 2016
  • Contemporary Therapeutics for Anaplastic Gliomas - Project #2 - Death Receptor Antibody Therapy for Anaplastic Glioma  awarded by National Cancer Institute/NIH/DHHS 2011 - 2016
  • UAB / UMN SPORE in Pancreatic Cancer - Project 3  awarded by National Cancer Institute/NIH/DHHS 2011 - 2016
  • UAB / UMN SPORE in Pancreatic Cancer - Career Development  awarded by National Cancer Institute/NIH/DHHS 2010 - 2016
  • UAB / UMN SPORE in Pancreatic Cancer - Core A  awarded by National Cancer Institute/NIH/DHHS 2010 - 2016
  • UAB / UMN SPORE in Pancreatic Cancer - Development  awarded by National Cancer Institute/NIH/DHHS 2010 - 2016
  • UAB / UMN SPORE in Pancreatic Cancer - Project 4  awarded by National Cancer Institute/NIH/DHHS 2010 - 2016
  • Wnt/B-Catenin Pathway as a Target for the Treatment of Ovarian Cancer  awarded by Foundation for Women's Cancer 2014 - 2016
  • Treatment of Ovarian Cancer with WNT/B-Catenin Inhibitors  awarded by American Association of Obstetricians and Gynecologists Foundation 2015
  • SPORE in Breast Cancer - Project 2  awarded by National Cancer Institute/NIH/DHHS 2007 - 2013
  • Sensitivity of Breast Cancer Stem Cells to TRA-8 Anti-DR5 Monoclonal Antibody  awarded by DOD - ARMY MEDICAL RESEARCH ACQUISITION ACTIVITY 2011 - 2013
  • SPORE in Breast Cancer - Project 5  awarded by National Cancer Institute/NIH/DHHS 2009 - 2012
  • Molecular Therapeutics for Anaplastic Gliomas - Project 3  awarded by National Cancer Institute/NIH/DHHS 2004 - 2011
  • Treatment of Ovarian Cancer with KiSS1 Metastasis Suppressor  awarded by KALEIDOSCOPE OF HOPE FOUNDATION 2010 - 2011
  • Comprehensive Cancer Center Core Support Grant - Major Program Leaders  awarded by National Cancer Institute/NIH/DHHS 2006 - 2011
  • Private Grant  awarded by DAIICHI SANKYO COMPANY LTD 2006 - 2008

    • Investigator On

  • Sialylation-dependent Mechanisms Driving Pancreatic Cancer Progression  awarded by National Cancer Institute/NIH/DHHS 2018 - 2023
  • Developing Novel Combination Therapies for Pancreatic Cancer  awarded by National Cancer Institute/NIH/DHHS 2016 - 2021
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS 2019 - 2021
  • Cervical Cancer Derived Xenografts (PDX) and Organoid Raft Cultures to Evaluate Pathway Specific Therapeutic Agents.  awarded by National Cancer Institute/NIH/DHHS 2019 - 2020
  • Targeting FCRL1 for Treatment in CLL  awarded by Leukemia and Lymphoma Society 2016 - 2019
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS 2017 - 2019
  • Treatment of Ovarian Cancer with WNT/B-Catenin Inhibitors  awarded by American Association of Obstetricians and Gynecologists Foundation 2015 - 2018
  • Glycosylation-Dependent Mechanisms Regulating Ovarian Tumor Cell Survival  awarded by National Institute of General Medical Sciences/NIH/DHHS 2014 - 2018
  • Glycan Control of Stem Cell-Associated Pathways in Pancreatic Cancer  awarded by National Cancer Institute/NIH/DHHS 2015 - 2017
  • Contemporary Therapeutics for Anaplastic Gliomas  awarded by National Cancer Institute/NIH/DHHS 2011 - 2017
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS 2016 - 2017
  • Lumina III System for UAB Optical Imaging  awarded by NIH - OFFICE OF THE DIRECTOR 2016 - 2017
  • Active - Major Program Leader - Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS 2011 - 2016
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS 2011 - 2016
  • Novel Anti-HER3 Strategy for Pancreatic Cancer  awarded by National Cancer Institute/NIH/DHHS 2013 - 2015
  • Targeting Death Receptors for the Treatment of Triple Negative Breast Cancer  awarded by Komen (Susan G.) Breast Cancer Foundation 2009 - 2015
  • Wnt/ß-catenin Pathway as a Target for the Treatment of Ovarian Cancer  awarded by Foundation for Women's Cancer 2014
  • SPORE in Breast Cancer  awarded by National Cancer Institute/NIH/DHHS 2007 - 2013
  • PKC/MARCKS Pathway as a Target for Radiation Sensitization  awarded by American Society for Therapeutic Radiology and Oncology 2008 - 2013
  • Death Receptor-Mediated Apoptosis and Therapy Strategies in Ovarian Cancer  awarded by National Cancer Institute/NIH/DHHS 2007 - 2013
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS 2006 - 2012
  • Joint Hudson Alpha UAB Project Global Genomic Analysis of Prostate, Breast, and Pancreatic Cancer  awarded by HUDSONALPHA INSTITUTE FOR BIOTECHNOLOGY 2010 - 2012
  • Private Grant  awarded by DAIICHI SANKYO COMPANY LTD 2006 - 2011
  • Molecular Therapeutics for Anaplastic Gliomas  awarded by National Cancer Institute/NIH/DHHS 2004 - 2011

    • Teaching Overview

  • Radiation biology

    • Awards And Honors

    Full Name

  • Donald Buchsbaum